Functional p53 determines docetaxel sensitivity in prostate cancer cells Article (Faculty180)

cited authors

  • Liu, Chengfei; Zhu, Yezi; Lou, Wei; Nadiminty, Nagalakshmi; Chen, Xinbin; Zhou, Qinghua; Shi, Xu B; deVere White, Ralph W; Gao, Allen C


  • Docetaxel is the first line treatment for castration resistant prostate cancer (CRPC). However, docetaxel resistance rapidly develops. Identifying the critical mechanisms giving rise to docetaxel resistance is the major challenge in advanced prostate cancer.

publication date

  • 2013

published in

start page

  • 418

end page

  • 27


  • 73